Vorinostat

Vorinostat is a drug that has received approval by the U.S. Food and Drug Administration under the brand name Zolinza for the treatment of a certain type of cancer. Vorinostat is also being studied as an investigational drug as part of a strategy to cure HIV infection. As an investigational HIV drug, vorinostat belongs to a group of drugs called latency-reversing agents. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Zolinza and Suberoylanilide hydroxamic acid. Its PubChem CID is 5311.

CAS No 149647-78-9
Molecular Formula C14H20N2O3
Molecular Weight 264.32 g/mol
Synonyms N'-hydroxy-N-phenyloctanediamide

Frequently Asked Questions